
Edwards Lifesciences (EW) Stock Forecast & Price Target
Edwards Lifesciences (EW) Analyst Ratings
Bulls say
Edwards Lifesciences is a standout company in the medical device industry, with a strong track record of success and innovation across its portfolio of heart valve products. Its recent quarter showed continued growth and strong performance in its transcatheter aortic valve business, and its plans for expanding into new areas like surgical tricuspid valve and left atrial appendage closure devices demonstrate its commitment to sustained growth. With a solid financial outlook, diverse product offerings, and a strong focus on patient access initiatives, Edwards Lifesciences is well-positioned for long-term success in the healthcare market.
Bears say
Edwards Lifesciences is expected to experience healthy growth due to its position as a leader in the structural heart disease market and potential for market expansion through guideline updates and new product launches. Despite a potential delay in the TAVR NCD and risks associated with commercial hiccups and competition, strong revenue guidance for the first quarter of 2026 and the company's solid growth profile make its stock a Buy with a $103 price target based on its strong multiple historically and potential for margin expansion.
This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.
Edwards Lifesciences (EW) Analyst Forecast & Price Prediction
Start investing in Edwards Lifesciences (EW)
Order type
Buy in
Order amount
Est. shares
0 shares